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Abstract Fidaxomicin is approved for the treatment of
adults with Clostridium difficile–associated diarrhea,
many of whom have difficulty swallowing an intact tablet.
The study objective was to evaluate the stability and
recovery of crushed DIFICID (fidaxomicin) 200-mg
tablets dispersed in water, applesauce, or Ensure brand
liquid nutritional supplement, and to determine the
recovery of fidaxomicin from the administration of an
aqueous dispersion of a crushed DIFICID tablet through
a nasogastric (NG) tube. DIFICID tablets were crushed
and dispersed in water, applesauce, or Ensure. The sta-
bility and recovery of fidaxomicin were evaluated over
24 h in these vehicles. In a separate experiment, the
ability to recover a full dose of fidaxomicin when
administering as an aqueous dispersion through an NG
tube was assessed. When DIFICID tablets were crushed
and dispersed in water, the active ingredient, fidaxomicin,
was stable for up to 2 h at room temperature. Addition-
ally, it was stable for up to 24 h in dispersions with
applesauce or Ensure. Recovery of fidaxomicin after
crushing and dispersing in any of the three vehicles
studied ranged from 95 to 108 %, which is within the
normal range of individual tablet variability. When cru-
shed, dispersed in water, and administered through an NG
tube, the average recovery of fidaxomicin was 96 %.
Stability and recovery of fidaxomicin were confirmed
when DIFICID tablets were crushed and dispersed in
water, applesauce, or Ensure. In addition, administration
of an aqueous dispersion of a crushed tablet through an
NG tube is supported by acceptable recovery of
fidaxomicin.
Key Points
Crushed DIFICID (fidaxomicin) 200-mg tablets are
stable and recoverable for at least 2 h after being
dispersed in water, applesauce, or Ensure at room
temperature.
The ability to administer aqueous dispersions
of crushed DIFICID tablets through a nasogastric
tube with acceptable recovery was demonstrated.
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1 Introduction
Clostridium difficile infection (CDI) is the most common
cause of healthcare facility–associated diarrhea and
accounts for 15–25 % of such infections [1]. The most
common symptom of CDI is C. difficile–associated diar-
rhea (CDAD). The rate of recurrent CDI is high, approxi-
mately 15–30 % [2–5], and can exceed 60 % in patients
with multiple episodes [6]. According to a recent report, C.
difficile may be exceeding methicillin-resistant Staphylo-
coccus aureus as the most prevalent healthcare facility–
acquired pathogen in the USA [7]. In 2009, there were
336,600 hospitalizations that involved CDI, accounting for
0.9 % of all hospital stays [8]; the annual incidence could
be hypothesized to exceed 1 million if other locations of
infection such as long-term care and outpatient settings are
considered.
Fidaxomicin, the active ingredient in DIFICID/DI-
FICLIR
TM
, is a macrocyclic antibiotic recently approved in
several countries, including the USA, for the treatment of
adults with CDAD [9]. It is nearly fully delivered to the
colon as a result of minimal systemic absorption [10]. The
efficacy of fidaxomicin was demonstrated in two large,
multicenter, randomized, double-blind, parallel-group,
noninferiority, phase III clinical trials [2, 3]. A total of
1,105 patients ages 18–94 years with either no prior
CDAD episode or one prior episode within the prior
3 months were treated orally with 200 mg of fidaxomicin
two times daily or 125 mg of vancomycin four times
daily for 10 days. In both studies, fidaxomicin was non-
inferior to vancomycin for initial clinical response,
whereas fidaxomicin was superior to vancomycin in
reducing recurrence and increasing sustained clinical
response, the latter defined as achieving clinical response
at the end of treatment and without proven or suspected
CDAD recurrence through the posttreatment observation
period of 28 days.
Whether because of increased age, critical illness, or
various other reasons, certain patients have difficulty
swallowing an intact tablet. It is, therefore, common prac-
tice to crush tablets and disperse them in liquids or soft
foods. The study presented here assesses the impact of such
practice on the stability and dose recovery of fidaxomicin
from DIFICID 200-mg tablets when crushed and dispersed
in water, applesauce, or Ensure. In a separate experiment,
the recovery of a full dose of an aqueous dispersion of a
crushed DIFICID tablet after being passed through a
nasogastric (NG) tube was examined. While a published
case report describes the administration of fidaxomicin
through an NG tube [11], the present study provides, to our
knowledge, the only rigorous study relevant to the stability
and recovery of crushed DIFICID tablets.
2 Methods and Materials
The stability and recovery of DIFICID (fidaxomicin)
200-mg tablets were evaluated after crushing and dispers-
ing single tablets in one of three vehicles: water, apple-
sauce (Mott’s Original Apple Sauce), or Ensure
(Ensure Nutrition Shake, Homemade Vanilla flavor,
Abbott Nutrition/Abbott Laboratories). Once dispersed, the
various presentations were assessed over a 24-h period for
stability and recovery of the expected dose of fidaxomicin
(200 mg). Stability was evaluated by the validated and
registered commercial product method for chromato-
graphic purity using high-performance liquid chromato-
graphy with ultraviolet detection (HPLC-UV).
Chromatographic purity values were calculated and
reported as the percentage active compared with a refer-
ence standard. The growth of new or existing impurities
was compared with product specifications to determine
acceptable stability. Recovery was measured using the
validated and registered commercial product method for
assay by HPLC-UV, with the potency of fidaxomicin cal-
culated against a reference standard of known concentra-
tion, and reported as percentage recovered of the labeled
tablet strength (200 mg).
For each of the three vehicles, two methods were used to
crush the DIFICID tablet. In the first method (Method 1),
the DIFICID tablet was placed in a polycarbonate pouch
and crushed using the Silent Knight tablet crushing system
(No. NONSK0100, Medline, Mundelein, IL, USA) (ADR-
11-027, Optimer Pharmaceuticals, 2011 October 10). In
Method 2, the DIFICID tablet was crushed between two
pieces of weighing paper using a pestle (ADR-12-003,
Optimer Pharmaceuticals, 2012 March 2). Crushed mate-
rial was then transferred, mixed with the test vehicle, and
stored at room temperature. Stability and recovery were
assessed over a 24-h period. For each time point, an indi-
vidually prepared sample of the dispersion was analyzed
for potency and chromatographic purity.
2.1 Water Sample Preparation
For each sample, one DIFICID (fidaxomicin) 200-mg
tablet was crushed and transferred to a flask, to which
40 mL of water was then added, and the contents were
mixed thoroughly by inversion. Flasks were stored at room
temperature, and at scheduled time points, samples were
310 A. Tousseeva et al.
prepared for HPLC-UV analysis by diluting with organic
solvent and centrifuging. A separate flask/preparation was
used for each time point.
2.2 Applesauce Sample Preparation
For each sample, one DIFICID (fidaxomicin) 200-mg
tablet was crushed and transferred to a flask containing
approximately 40 mL of applesauce. The contents were
then mixed by shaking and rolling the flask. Flasks were
stored at room temperature, and at scheduled time points,
samples were prepared for HPLC-UV analysis by diluting
with organic solvent and centrifuging. A separate flask/
preparation was used for each time point.
2.3 Ensure Sample Preparation
For each sample, one DIFICID (fidaxomicin) 200-mg
tablet was crushed and transferred to a flask, to which 60 mL
of Ensure was then added, and the contents were mixed by
shaking the flask. Flasks were stored at room temperature,
and at scheduled time points, 100 mL of organic solvent was
added and the flask contents were mixed by swirling gently.
In order to achieve organic/water layer separation, sodium
chloride was added to the mixture. An aliquot of the organic
layer was centrifuged, and a portion of the resulting super-
natant was further diluted for HPLC-UV analysis. A sepa-
rate flask/preparation was used for each time point.
2.4 Passage Through a Nasogastric (NG) Tube
For each sample, one DIFICID (fidaxomicin) 200-mg
tablet was crushed using Method 2 and transferred to a
100-mL volumetric flask. Approximately 40 mL of distilled
water was then added to the flask; contents were mixed
thoroughly by hand, and then shaken on an orbital shaker for
15 min. Contents were verified by visual inspection to be
completely disintegrated, and the flask was brought up to the
volume by addition of distilled water. The aqueous disper-
sion was then passed through a size 10 Fr (3.3 mm) 9 45-
inch NG enteral feeding tube with twin-port and stylet
(ADR-11-0002, Optimer Pharmaceuticals, 2011 November
15) and subsequently collected for analysis. To achieve this,
each NG tube was attached to a 50-mL syringe with the
plunger removed and a 200-mL volumetric flask was placed
at the other end of the NG tube for collection. The aqueous
dispersion was slowly poured into the syringe, allowing it to
drain through the NG tube under gravity into the collection
flask. The original flask containing the aqueous fidaxomicin
dispersion was then rinsed twice with 15 mL of water. Each
of these rinses was poured into the syringe and allowed to
drain through the NG tube into the collecting flask. The
plunger was then attached to the syringe and depressed to
expel any remaining dispersion from the syringe and the NG
tube. The receiving flask was brought up to volume and
samples were prepared for HPLC-UV analysis by diluting
with organic solvent and centrifuging. Three separate sam-
ples were prepared in this fashion.
3 Results
3.1 Water Vehicle
The stability and recovery of fidaxomicin in water
over 24 h are shown in Table 1A. The recovery of fi-
daxomicin after aqueous dispersion was acceptable for
both crushing methods, with Method 1 yielding recov-
eries of 95–104 % and Method 2 yielding recoveries of
102–104 %. All results were within the normal variability
for individual DIFICID tablets as defined in the product
specifications.
Multiple degradation products were observed in the
chromatographic purity assessment of crushed DIFICID
tablets dispersed in water. However, only one impurity,
designated Impurity A, was observed to exceed the speci-
fication limit of 0.2 % during the course of the 24-h study
using either crushing method. Growth of this impurity was
used to define the acceptable stability of crushed DIFICID
tablets dispersed in water. The amount of Impurity A
exceeded the limit at 6 h (0.25 %) in the Method 2 study;
thus the stability of crushed DIFICID tablets dispersed in
water was assigned to be 2 h at room temperature. Figure 1
shows the linear increase in Impurity A from 0 to 12 h
from the Method 2 study data.
3.2 Applesauce Vehicle
The recovery of fidaxomicin ranged from 105 to 108 % for
Method 1 and 102–105 % for Method 2 over the 24-h
period (Table 1B). All results were within the normal
variability for individual DIFICID tablets, as defined in
the product specifications.
After 24 h at room temperature, all impurities were
below drug product specification limits (Table 1B). This
supports the stability of fidaxomicin for up to 24 h when
dispersed in applesauce and stored at ambient room
temperature.
3.3 Ensure Vehicle
The recovery of fidaxomicin ranged from 96 to 99 % in
Method 1 and 105–108 % in Method 2 over the 24-h
period (Table 1C). All results were within the normal
variability for individual DIFICID tablets, as defined in
the product specifications.
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After 24 h at room temperature, all impurities were
below drug product specification limits (Table 1C). This
supports the stability of fidaxomicin for up to 24 h when
dispersed in Ensure.
3.3.1 Note on Crushing
It should be noted that some loss of tablet powder to the
pouch used in crushing Method 1 was visually observed. In
a separate weight-based experiment, the average loss was
determined to be about 6 %. Though the measured recov-
ery values are acceptable, when using a pouch-based sys-
tem, care should be exercised to minimize material loss.
3.4 Recovery from an NG Tube
There was no visible tablet material or film-coating residue
detected after administration of the aqueous fidaxomicin
dispersion and rinsing with water as described. Visual
inspection for assessment of clumping and particle
adsorption to the interior of the NG tubing revealed no
Table 1 Stability and recovery of fidaxomicin dispersed in water, applesauce, or Ensure
Time (h)
0 2 6 12 24
A. Water
Method 1
% Recovery, mean (SD) (n = 3) 95.3 (2.32) nt 104.4 (3.07) nt 100.6 (2.23)
% Impurity Aa \LOQ nt 0.19 nt 0.65
Method 2
% Recovery, mean (SD) (n = 6) 103.8 (1.28) 102.9 (1.57) 102.2 (1.49) 104.1 (1.13) nt
% Impurity Aa \LOQ 0.11 0.25 0.38 nt
B. Applesauce
Method 1
% Recovery, mean (SD) (n = 3) 105.0 (1.37) nt 108.2 (4.29) nt 104.6 (2.22)
% Impurity Aa \LOQ nt \LOQ nt \LOQ
Method 2
% Recovery, mean (SD) (n = 6) 104.8 (1.20) nt 104.5 (1.05) 101.7 (1.96) 104.6 (0.80)
% Impurity Aa \LOQ nt \LOQ \LOQ \LOQ
C. Ensure
Method 1
% Recovery, mean (SD) (n = 3) 95.5 (3.41) nt 99.1 (5.92) nt 99.0 (3.87)
% Impurity Aa \LOQ nt \LOQ nt 0.08
Method 2
% Recovery, mean (SD) (n = 6) 105.6 (1.03) nt 107.7 (1.35) 105.4 (1.48) 107.8 (1.71)
% Impurity Aa \LOQ nt 0.06 0.06 0.14
h hour, LOQ limit of quantification (0.05 %), nt not tested, SD standard deviation
a Limit in drug product is not more than 0.2 %
Fig. 1 Linear regression plot of Impurity A in a water matrix
(Method 2)
312 A. Tousseeva et al.
deficiencies. The percent recovery of fidaxomicin was
C93 % for all three runs, with an average recovery of 96 %
(Table 2).
4 Discussion
Prior to this study, no information had been available
regarding (1) the stability and recovery of DIFICID
(fidaxomicin) 200-mg tablets when crushed and dispersed
in assorted oral delivery vehicles, including water, apple-
sauce, and Ensure; and (2) the recovery of aqueous
fidaxomicin dispersions after being passed through an NG
tube. Drug impurities and degradation products remained
within specifications for 2 h when dispersed in water and
for at least 24 h when dispersed in applesauce or Ensure
under ambient room temperature conditions. This demon-
strates that crushed and dispersed DIFICID tablets are
stable under such conditions. Recovery of fidaxomicin
from crushed DIFICID tablets was within normal tablet
variability for all conditions and vehicles studied, indicat-
ing that the expected amount of fidaxomicin can be
delivered after crushing and dispersing DIFICID tablets
in water, applesauce, or Ensure. Additionally, acceptable
recovery of fidaxomicin has been demonstrated after
passing aqueous dispersions of crushed DIFICID tablets
through a representative NG tube.
On the basis of these data, crushing a DIFICID (fidax-
omicin) 200-mg tablet and dispersing it in three common
vehicles (water, applesauce, or Ensure) does not negatively
impact the key quality parameters of purity and potency of
the administered drug product. The active ingredient, fi-
daxomicin, is stable and recoverable under these conditions.
5 Conclusion
It is a common practice to crush solid oral formulations,
such as tablets, and disperse them in various vehicles to
facilitate administration, including NG tube administration
in water, to patients who have difficulty swallowing. This
study has demonstrated that the stability and ability to
deliver the expected dose of fidaxomicin is not negatively
impacted by such practices. Crushed DIFICID
(fidaxomicin) 200-mg tablets are stable and recoverable for
at least 2 h after being dispersed in water, applesauce, or
Ensure under ambient room temperature conditions. This
window of stability should provide sufficient time for the
preparation and administration of crushed DIFICID tab-
lets for this alternative means of dosing. The ability to
administer aqueous dispersions of crushed DIFICID tab-
lets through an NG tube with acceptable recovery was also
demonstrated. Future work could potentially focus on for-
mulating a stable suspension or solution.
The manuscript does not contain clinical studies or
patient data.
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